Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice

Human respiratory syncytial virus (RSV) is a common cause of respiratory infections in infants, young children, and elderly people. However, there are no effective treatments or vaccines available in most countries. In this study, we explored the anti-RSV potential of 2, 4-Di-tert-butylphenol (2, 4-...

Full description

Saved in:
Bibliographic Details
Published inAntiviral research Vol. 226; p. 105880
Main Authors Guo, Mingyang, Peng, Jianqing, Guo, Pengcheng, Wang, Qin, Zhang, Lin, Shen, Huyan, Chen, Fang, Zhang, Pingping, Lin, Siyu, Gao, Han, Peng, Hong, Mou, Rong, Huang, Jiandong, Wang, Jianxin, Luo, Yu-Si, Zhang, Ke
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human respiratory syncytial virus (RSV) is a common cause of respiratory infections in infants, young children, and elderly people. However, there are no effective treatments or vaccines available in most countries. In this study, we explored the anti-RSV potential of 2, 4-Di-tert-butylphenol (2, 4-DTBP), a compound derived from Houttuynia cordata Thunb. To overcome the poor solubility of 2, 4-DTBP, we encapsulated it in polymeric micelles and delivered it by inhalation. We found that 2, 4-DTBP-loaded micelles inhibited RSV infection in vitro and improved survival, lung pathology, and viral clearance in RSV-infected mice. Our results suggested that 2, 4-DTBP-loaded micelle is a promising novel therapeutic agent for RSV infection. •2, 4-DTBP-loaded micelles could inhibit RSV propagation in vitro.•A lethal RSV infection mice model was established.•2, 4-DTBP-loaded micelles could alleviate lethal RSV infection in vivo.•Polymeric micelles could enhance the solubility of 2, 4-DTBP to achieve anti-RSV effect thereafter.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2024.105880